{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:31:30Z","timestamp":1781008290734,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16414"],"award-info":[{"award-number":["19K16414"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinthera.2021.09.007","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T13:51:22Z","timestamp":1633960282000},"page":"1910-1920.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Area Under the Concentration\u2013Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam\/Piperacillin or Cefepime: A Single-Institution Retrospective Study"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-9191","authenticated-orcid":false,"given":"Naoto","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoyo","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.09.007_bib0001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/phar.2388","article-title":"Vancomycin-induced kidney injury: animal models of toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention","volume":"40","author":"Pais","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.09.007_bib0002","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0005","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/1060028017716469","article-title":"Vancomycin trough concentration poorly characterizes AUC: is it time to transition to AUC-based vancomycin monitoring?","volume":"51","author":"Seabury","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0006","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1373\/jalm.2018.027391","article-title":"AUC-based monitoring of vancomycin: closing the therapeutic window","volume":"3","author":"Biagi","year":"2019","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106109","article-title":"Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 \u03bcg\/mL concentration","volume":"56","author":"Oda","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0008","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0009","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0012","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijantimicag.2018.03.024","article-title":"Nephrotoxicity of piperacillin\/tazobactam combined with vancomycin: should it be a concern?","volume":"52","author":"Balci","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0013","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106234","article-title":"Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury","volume":"57","author":"Muklewicz","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00228-019-02694-1","article-title":"Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?","volume":"75","author":"Heffernan","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0016","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/jcpt.13249","article-title":"Vancomycin plus piperacillin\/tazobactam and acute kidney injury risk: a review of the literature","volume":"45","author":"Covert","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0017","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1248\/bpb.b19-00652","article-title":"Augmented renal clearance of vancomycin in hematologic malignancy patients","volume":"42","author":"Izumisawa","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0018","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00228-019-02756-4","article-title":"Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study","volume":"75","author":"Okada","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0019","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application","author":"Oda","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0022","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00228-019-02661-w","article-title":"Relationship between hemoglobin levels and vancomycin clearance in patients with sepsis","volume":"75","author":"Chuma","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/kisup.2012.7","article-title":"Summary of recommendation statements","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0024","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0025","first-page":"1","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review","author":"Blair","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0027","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0028","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/cid\/cix675","article-title":"Increasing evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy-what is the clinician to do?","volume":"65","author":"Watkins","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0029","doi-asserted-by":"crossref","first-page":"ofaa538","DOI":"10.1093\/ofid\/ofaa538","article-title":"Vancomycin exposure and acute kidney injury outcome: a snapshot from the CAMERA2 study","volume":"7","author":"Liu","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13318-019-00551-1","article-title":"Clinical and pharmacokinetic outcomes of peak-trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: a pragmatic randomized controlled trial","volume":"44","author":"Al-Sulaiti","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11096-020-01157-3","article-title":"Evaluation of a trough-only extrapolated area under the curve vancomycin dosing method on clinical outcomes","volume":"43","author":"Lines","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0032","first-page":"61","article-title":"Pilot study of a Bayesian approach to estimate vancomycin exposure in obese patients with limited pharmacokinetic sampling","author":"Carreno","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0033","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/IDR.S239095","article-title":"A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia","volume":"13","author":"He","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.clinthera.2021.09.007_bib0034","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","article-title":"The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults","volume":"75","author":"Bury","year":"2019","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:05Z","timestamp":1758963365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182100360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S014929182100360X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Area Under the Concentration\u2013Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam\/Piperacillin or Cefepime: A Single-Institution Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}